COMPARATIVE CHARACTERISTICS OF HORMONAL INDICATORS IN INFERTILE WOMEN WITH POLYCYSTIC OVARY SYNDROME AND METABOLIC SYNDROME
DOI:
https://doi.org/10.11603/1811-2471.2025.v.i3.15575Keywords:
infertility, polycystic ovary syndrome, hormonal imbalance, anti-Müllerian hormone, hyperandrogenism, testosterone, metabolic syndrome, sex hormones, in vitro fertilization, assisted reproductive technologies, embryosAbstract
Summary. Polycystic ovary syndrome (PCOS) is a leading cause of endocrine infertility. A distinct clinical subgroup includes women with PCOS combined with metabolic syndrome, characterized by more pronounced metabolic and hormonal disturbances, which may complicate infertility management and treatment response. Therefore, the aim of this study was to investigate the hormonal profile and identify clinically significant hormonal markers with diagnostic and prognostic value in patients with PCOS and metabolic syndrome, to better predict reproductive function and optimize assisted reproductive technology (ART) protocols in these patients.
Material and Methods. A retrospective comparative analysis was conducted to assess the hormonal profile by measuring serum levels of key sex hormones (FSH, LH, LH/FSH ratio, prolactin, estradiol, total and free testosterone, progesterone, anti-Müllerian hormone (AMH)) based on clinical and laboratory data from reproductive-age women with various forms of infertility.
Results. Women with PCOS exhibited a characteristic hormonal imbalance: elevated levels of LH, prolactin, total and free testosterone, and increased LH/FSH ratio alongside decreased levels of FSH, estradiol, and progesterone. These changes correspond to impaired ovulatory function and folliculogenesis, which are typical features of this pathology.
Conclusions. The coexistence of PCOS and metabolic syndrome exacerbates hormonal disturbances, promoting hyperandrogenism and anovulation. The obtained data support the necessity of comprehensive hormonal assessment when selecting treatment strategies, especially in the context of ART.
References
Hoeger KM, Dokras A, & Piltonen T. Update on PCOS: Consequences, Challenges, and Guiding Treatment. The Journal of Clinical Endocrinology & Metabolism. 2020. DOI: 10.1210/clinem/dgaa839 DOI: https://doi.org/10.1210/clinem/dgaa839
Ahmad AK, Quinn M, Kao C-N, Greenwood E, Cedars MI, & Huddleston, HG. Improved diagnostic performance for the diagnosis of polycystic ovary syndrome using age-stratified criteria. Fertility and Sterility, 2019; 111(4):787–793.e2. DOI: 10.1016/j.fertnstert. 2018.11.044 DOI: https://doi.org/10.1016/j.fertnstert.2018.11.044
Forslund M, Schmidt J, Brännström M, Landin-Wilhelmsen K, & Dahlgren E. Reproductive Hormones and Anthropometry: A Follow-Up of PCOS and Controls From Perimenopause to Older Than 80 Years. The Journal of Clinical Endocrinology & Metabolism. 2020. DOI: 10.1210/clinem/dgaa840 DOI: https://doi.org/10.1210/clinem/dgaa840
Le NSV, Le MT, Nguyen ND, Tran NQT, Nguyen QHV, & Cao TN. A Cross-Sectional Study on Potential Ovarian Volume and Related Factors in Women with Polycystic Ovary Syndrome from Infertile Couples. International Journal of Women's Health. 2021; 13:793–801. DOI: 10.2147/ijwh.s329082 DOI: https://doi.org/10.2147/IJWH.S329082
Zhuang S, Jing C, Yu L, Ji L, Liu W, & Hu X. The relationship between polycystic ovary syndrome and infertility: a bibliometric analysis. Annals of Translational Medicine. 2022; 10(6): 318. DOI: 10.21037/atm-22-714 DOI: https://doi.org/10.21037/atm-22-714
He Y, Lu Y, Zhu Q, Wang Y, Lindheim SR, Qi J, Li X, Ding Y, Shi Y, Wei D, Chen Z-J, & Sun Y. Influence of metabolic syndrome on female fertility and in vitro fertilization outcomes in PCOS women. American Journal of Obstetrics and Gynecology. 2019;221(2):138.e1–138.e12. DOI: 10.1016/j.ajog.2019.03.011 DOI: https://doi.org/10.1016/j.ajog.2019.03.011
Kicińska AM, Maksym RB, Zabielska-Kaczorowska MA, Stachowska A, & Babińska A. Immunological and Metabolic Causes of Infertility in Polycystic Ovary Syndrome. Biomedicines, 2023;11(6):1567. DOI:10.3390/biomedicines11061567 DOI: https://doi.org/10.3390/biomedicines11061567
Zheng X, Guo W, Zeng L, Zheng D, Yang S, Xu Y, Wang L, Wang R, Mol BW, Li R, & Qiao J. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial. Human Reproduction, 2021; 37(2):242–253. DOI: 10.1093/humrep/deab243
Su P, Chen C, & Sun Y. Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. Journal of Ovarian Research. 2025;18(1). DOI: 10.1186/s13048-025-01621-6 DOI: https://doi.org/10.1186/s13048-025-01621-6
Zheng X, Guo W, Zeng L, Zheng D, Yang S, Xu Y, Wang L, Wang R, Mol BW, LiR, & Qiao J. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial. Human Reproduction. 2021; 37(2):242–253. DOI: 10.1093/humrep/deab243 DOI: https://doi.org/10.1093/humrep/deab243
Yang Y, Ouyang N, Ye Y, Hu Q, Du T, Di N, Xu W, Azziz R, Yang D, & Zhao X. The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome. Reproductive BioMedicine Online. 2020;41(4):734–742. DOI: 10.1016/j.rbmo.2020.07.013 DOI: https://doi.org/10.1016/j.rbmo.2020.07.013
Imran HJ, Dhaher SA, & Mansour AA. Testosterone or Dehydroepiandrosterone Sulfate as a Biomarker for Hirsutism in Women with Polycystic Ovary Syndrome. Biomedical and Pharmacology Journal. 2020;13(4):1815–1823. DOI: 10.13005/bpj/2056 DOI: https://doi.org/10.13005/bpj/2056
Rudnicka E, Kunicki M, Calik-Ksepka A, Suchta K, Duszewska A, Smolarczyk K, & Smolarczyk R. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS. International Journal of Molecular Sciences. 2021; 22(22):12507. DOI: 10.3390/ijms222212507 DOI: https://doi.org/10.3390/ijms222212507
